期刊
BLOOD REVIEWS
卷 27, 期 6, 页码 261-267出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2013.08.002
关键词
Myeloma bone disease; DKK1; Antibody; Proteasome inhibitor; Vaccine
类别
资金
- National Natural Science Foundation of China [81172257]
- Xi'an Fundamental Research Funds of China [HM1117-4]
- National Cancer Institute [RO1-CA90853]
- National Institutes of Health through the University of Texas MD Anderson Cancer Center Support Grant [CA016672]
Myeloma bone disease (MBD) is the most visible aspect of plasma cell myeloma (PCM), which is characterized by the displacement of hematopoiesis and the formation of osteolytic bone lesions. The secreted glycoprotein Dickkopf-1 (DKK1), an inhibitor of the Wnt signaling pathway, is broadly expressed in myeloma cells but highly restricted in normal tissues. DKK1 plays a critical role in several aspects of bone biology and actively participates in regulating MBD by inhibiting osteoblasts and by activating osteoclasts. Based on these findings, ongoing research has been targeting DKK1 to find novel therapeutic strategies for MBD, such as DIM-neutralizing antibodies, proteasome inhibitors, and vaccines. All these strategies have produced encouraging clinical results and consequently, revealed the significance of DKK1 in MBD. This review discusses the recent advances in our understanding of the DIM pathway signaling and how DIM can be exploited in the therapeutic intervention of MBD. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据